Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$21.33 +2.8%	$17.10	$9.57 ▼ $27.34	$2.87B	0.94	2.27 million shs	2.65 million shs
BLTE Belite Bio	$64.40 -1.2%	$63.06	$43.70 ▼ $86.53	$2.08B	-1.49	47,683 shs	24,096 shs
CNTA Centessa Pharmaceuticals	$17.01 -3.0%	$15.28	$9.60 ▼ $19.09	$2.35B	1.48	1.17 million shs	1.13 million shs
TBPH Theravance Biopharma	$13.91 +1.8%	$11.48	$7.88 ▼ $14.30	$687.93M	0.01	386,905 shs	846,056 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+2.80%	+4.00%	+33.98%	+40.98%	-15.49%
BLTE Belite Bio	-1.23%	-3.35%	+3.35%	+5.57%	+30.87%
CNTA Centessa Pharmaceuticals	-2.97%	-5.76%	+9.25%	+32.17%	+39.31%
TBPH Theravance Biopharma	+1.83%	+5.78%	+23.10%	+49.57%	+73.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.7439 of 5 stars	3.5	1.0	3.4	2.7	2.5	0.0
BLTE Belite Bio	2.6045 of 5 stars	3.5	4.0	0.0	1.6	0.8	0.6
CNTA Centessa Pharmaceuticals	2.1641 of 5 stars	3.5	1.0	0.0	1.5	2.5	0.6
TBPH Theravance Biopharma	2.1407 of 5 stars	3.8	0.0	0.0	1.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	102.26% Upside
BLTE Belite Bio	3.00	Buy	$96.67	50.10% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$28.10	65.20% Upside
TBPH Theravance Biopharma	3.50	Strong Buy	$21.33	53.37% Upside

Current Analyst Ratings Breakdown

Latest TBPH, CNTA, ARWR, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/3/2025	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
6/27/2025	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
6/17/2025	TBPH Theravance Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$24.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	830.73	N/A	N/A	$3.76 per share	5.67
BLTE Belite Bio	N/A	N/A	N/A	N/A	$4.71 per share	N/A
CNTA Centessa Pharmaceuticals	$6.85M	332.53	N/A	N/A	$2.58 per share	6.59
TBPH Theravance Biopharma	$64.38M	10.88	N/A	N/A	$4.46 per share	3.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	N/A	N/A	-40.91%	-11.62%	N/A
BLTE Belite Bio	-$36.14M	-$1.55	N/A	N/A	N/A	N/A	-34.90%	-33.56%	11/11/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.79	N/A	N/A	N/A	N/A	-40.39%	-29.87%	11/11/2025 (Estimated)
TBPH Theravance Biopharma	-$56.42M	$0.24	57.96	39.74	N/A	16.88%	6.93%	3.52%	11/11/2025 (Estimated)

Latest TBPH, CNTA, ARWR, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.38	-$0.03	-$0.38	$0.63 million	N/A
8/11/2025	Q2 2025	BLTE Belite Bio	-$0.47	-$0.50	-$0.03	-$0.50	N/A	N/A
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
BLTE Belite Bio	N/A	23.15	23.15
CNTA Centessa Pharmaceuticals	0.32	10.11	10.12
TBPH Theravance Biopharma	N/A	6.70	6.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BLTE Belite Bio	0.53%
CNTA Centessa Pharmaceuticals	82.01%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BLTE Belite Bio	13.29%
CNTA Centessa Pharmaceuticals	7.09%
TBPH Theravance Biopharma	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
BLTE Belite Bio	10	31.84 million	27.61 million	Not Optionable
CNTA Centessa Pharmaceuticals	200	133.91 million	124.42 million	Optionable
TBPH Theravance Biopharma	110	50.36 million	46.89 million	Optionable

TBPH, CNTA, ARWR, and BLTE Headlines

Recent News About These Companies

Theravance Biopharma Settles Patent Dispute with Cipla

August 20 at 7:34 PM | msn.com

Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's What Happened

August 20 at 11:47 AM | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Upgraded at Wall Street Zen

August 19, 2025 | americanbankingnews.com

Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen

August 17, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Up 3.4% - Here's Why

August 16, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High on Earnings Beat

August 14, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

August 14, 2025 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High on Strong Earnings

August 14, 2025 | americanbankingnews.com

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

August 13, 2025 | zacks.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Theravance Biopharma Inc (TBPH) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Theravance Biopharma reports Q2 EPS $1.08 with items, consensus (12c)

August 12, 2025 | msn.com

Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

August 12, 2025 | zacks.com

Theravance Bio: Q2 Earnings Snapshot

August 12, 2025 | timesunion.comT

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | prnewswire.com

Theravance Biopharma Q2 2025 Earnings Preview

August 11, 2025 | msn.com

Theravance Biopharma (TBPH) to Release Earnings on Monday

July 28, 2025 | marketbeat.com

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

July 28, 2025 | prnewswire.com

Theravance Biopharma to Participate in an Upcoming Investor Conference

July 23, 2025 | prnewswire.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH, CNTA, ARWR, and BLTE Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$21.33 +0.58 (+2.80%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$21.35 +0.02 (+0.08%)

As of 08/22/2025 06:00 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Belite Bio NASDAQ:BLTE

$64.40 -0.80 (-1.23%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$64.98 +0.58 (+0.90%)

As of 08/22/2025 04:10 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Centessa Pharmaceuticals NASDAQ:CNTA

$17.01 -0.52 (-2.97%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.47 +0.46 (+2.73%)

As of 08/22/2025 07:57 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Theravance Biopharma NASDAQ:TBPH

$13.91 +0.25 (+1.83%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$13.91 0.00 (0.00%)

As of 08/22/2025 04:10 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time